Lipocine Inc.
LPCN
$1.98
-$0.07-3.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 119.40K | 1.15M | 114.60K | 622.80K | 93.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 119.40K | 1.15M | 114.60K | 622.80K | 93.90K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 119.40K | 1.15M | 114.60K | 622.80K | 93.90K |
| SG&A Expenses | 1.20M | 983.40K | 767.80K | 890.40K | 1.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.97M | 3.66M | 3.48M | 3.03M | 2.18M |
| Operating Income | -3.85M | -2.52M | -3.36M | -2.40M | -2.09M |
| Income Before Tax | -3.67M | -2.37M | -3.19M | -2.21M | -1.86M |
| Income Tax Expenses | -- | 0.00 | -- | -- | 200.00 |
| Earnings from Continuing Operations | -3.67M | -2.37M | -3.19M | -2.21M | -1.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.67M | -2.37M | -3.19M | -2.21M | -1.86M |
| EBIT | -3.85M | -2.52M | -3.36M | -2.40M | -2.09M |
| EBITDA | -3.83M | -2.50M | -3.35M | -2.39M | -2.07M |
| EPS Basic | -0.54 | -0.42 | -0.59 | -0.41 | -0.35 |
| Normalized Basic EPS | -0.34 | -0.26 | -0.37 | -0.26 | -0.22 |
| EPS Diluted | -0.54 | -0.42 | -0.59 | -0.41 | -0.35 |
| Normalized Diluted EPS | -0.34 | -0.26 | -0.37 | -0.26 | -0.22 |
| Average Basic Shares Outstanding | 6.80M | 5.68M | 5.41M | 5.35M | 5.35M |
| Average Diluted Shares Outstanding | 6.80M | 5.68M | 5.41M | 5.35M | 5.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |